1
|
Cantley NWP, Barski R, Kemp H, Hogg SL, Wu HYT, Bowron A, Collingwood C, Cundick J, Hart C, Shakespeare L, Preece MA, Aitkenhead H, Smith S, Carling RS, Moat SJ. Incidental Detection of Classical Galactosemia through Newborn Screening for Phenylketonuria: A 10-Year Retrospective Audit to Determine the Efficacy of This Approach. Int J Neonatal Screen 2023; 10:2. [PMID: 38248630 PMCID: PMC10801530 DOI: 10.3390/ijns10010002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 12/12/2023] [Accepted: 12/15/2023] [Indexed: 01/23/2024] Open
Abstract
In the UK, Classical Galactosaemia (CG) is identified incidentally from the Newborn Screening (NBS) for phenylketonuria (PKU) using an "Other disorder suspected" (ODS) pathway when phenylalanine (Phe) and tyrosine (Tyr) concentrations are increased. We aimed to determine the efficacy of CG detection via NBS and estimate the incidence of CG in live births in the UK. A survey was sent to all UK NBS laboratories to collate CG cases diagnosed in the UK from 2010 to 2020. Cases of CG diagnosed were determined if detected clinically, NBS, or by family screening, as well as age at diagnosis. Cases referred via the ODS pathway were also collated, including the final diagnosis made. Responses were obtained from 13/16 laboratories. Between 2010 and 2020, a total of 6,642,787 babies were screened, and 172 cases of CG were identified. It should be noted that 85/172 presented clinically, 52/172 were identified by NBS, and 17/172 came from family screening. A total of 117 referrals were made via the ODS pathway, and 45/117 were subsequently diagnosed with CG. Median (interquartile range) age at diagnosis by NBS and clinically was 8 days (7-11) and 10 days (7-16), respectively (Mann-Whitney U test, U = 836.5, p-value = 0.082). The incidence of CG is 1:38,621 live births. The incidence of CG in the UK is comparable with that of other European/western countries. No statistical difference was seen in the timing of diagnosis between NBS and clinical presentation based on the current practice of sampling on day 5. Bringing forward the day of NBS sampling to day 3 would increase the proportion diagnosed with CG by NBS from 52/172 (30.2%) to 66/172 (38.4%).
Collapse
Affiliation(s)
- Nathan W. P. Cantley
- South West Newborn Screening and Metabolic Laboratory, Severn Pathology, Southmead Hospital, Bristol BS10 5NB, UK
| | - Robert Barski
- Biochemical Genetics, Specialist Laboratory Medicine, Block 46, St James University Hospital, Leeds LS9 7TF, UK;
| | - Helena Kemp
- South West Newborn Screening and Metabolic Laboratory, Severn Pathology, Southmead Hospital, Bristol BS10 5NB, UK
| | - Sarah L. Hogg
- Biochemical Genetics Unit, Cambridge University Hospitals, Cambridge CB2 0QQ, UK
| | - Hoi Yee Teresa Wu
- Willink Biochemical Genetics Laboratory, Genomic Medicine, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK
| | - Ann Bowron
- Metabolic and Newborn Screening Section, Department of Blood Sciences, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle-Upon-Tyne NE1 4LP, UK
| | - Catherine Collingwood
- Biochemistry Department, Alder Hey Children’s NHS Foundation Trust, Liverpool L12 2AP, UK
| | - Jennifer Cundick
- Regional Newborn Screening Laboratory, Royal Victoria Hospital, Belfast BT12 6BA, UK
| | - Claire Hart
- Department of Clinical Chemistry and Newborn Screening, Sheffield Children’s Hospital, Sheffield S10 2TH, UK
| | - Lynette Shakespeare
- Department of Clinical Chemistry and Newborn Screening, Sheffield Children’s Hospital, Sheffield S10 2TH, UK
| | - Mary Anne Preece
- Newborn Screening and Biochemical Genetics, Paediatric Laboratory Medicine, Birmingham Children’s Hospital, Steelhouse Lane, Birmingham B4 6NH, UK
| | - Helen Aitkenhead
- Department of Chemical Pathology, Great Ormond Street Hospital for Children, London WC1N 3JH, UK
| | - Sarah Smith
- Scottish Newborn Screening Laboratory, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK
| | - Rachel S. Carling
- Biochemical Sciences, Synnovis, Guys & St Thomas’ NHS Foundation Trust, London SE1 7EH, UK
- GKT School Medical Education, Kings College London, London WC2R 2LS, UK
| | - Stuart J. Moat
- Department of Medical Biochemistry, Immunology & Toxicology, University Hospital Wales, Cardiff CF14 4XW, UK;
- School of Medicine, Cardiff University, Cardiff CF14 4XW, UK
| |
Collapse
|
2
|
Pearson J, Khan A, Bhogal T, Wong H, Law A, Mills S, Santamaria N, Bishop J, Cliff J, Errington D, Hall A, Hart C, Malik Z, Sripadam R, Innes H, Flint H, Langton G, Ahmed E, Jackson R, Palmieri C. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone. ESMO Open 2023; 8:102033. [PMID: 37866031 PMCID: PMC10774880 DOI: 10.1016/j.esmoop.2023.102033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 08/29/2023] [Accepted: 09/18/2023] [Indexed: 10/24/2023] Open
Abstract
BACKGROUND Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in patients with brain metastasis (BM), a group historically with poor outcomes. The prevalence of BMs in patients commencing T-DXd is currently unknown. No direct comparisons have been made of the activity of T-DXd in patients with active BM versus those with extracranial progression alone. This real-world study explored the prevalence of BMs in patients commencing T-DXd, the efficacy of T-DXd in active BM versus extracranial progression alone and the safety of T-DXd. PATIENTS AND METHODS Patients with human epidermal growth factor receptor 2-positive advanced breast cancer treated with T-DXd between June 2021 and February 2023 at our specialist cancer hospital were identified and notes reviewed. Clinicopathological information, prior treatment, the presence or absence of central nervous system (CNS) disease, outcomes and treatment-emergent adverse events (TEAEs) were recorded. RESULTS Twenty-nine female patients, with a median age of 52 years (interquartile range 44-62 years), were identified; the prevalence of BM was 41%. Median number of lines of prior therapy was 2 (range 2-6). At a median follow-up of 13.8 months, median progression-free survival (PFS) for the overall population was 13.9 months [95% confidence interval (CI) 12.4 months-not estimable (NE)], 16.1 months (95% CI 15.1 months-NE) for active BMs and 12.4 months (95% CI 8.3 months-NE) for progressive extracranial disease alone. The 12-month overall survival (OS) rate was 74% (95% CI 59% to 95%) in the overall population, and 83% (95% CI 58% to 100%) and 66% (95% CI 45% to 96%) for active BMs and extracranial disease only, respectively. Most common TEAEs were fatigue, alopecia, and constipation. In nine patients (31%, including two deaths), pneumonitis occurred. CONCLUSION In this real-world population, we demonstrate T-DXd to be effective in patients with active BMs and those with progressive extracranial disease alone. PFS and OS were numerically longer in those with active BMs. These data demonstrate that patients with active BM treated with T-DXd have at least comparable outcomes to those with extracranial disease alone. The high rate of pneumonitis warrants further consideration.
Collapse
Affiliation(s)
- J Pearson
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool
| | - A Khan
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - T Bhogal
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool
| | - H Wong
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - A Law
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - S Mills
- The Walton NHS Foundation Trust, Liverpool, UK
| | - N Santamaria
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - J Bishop
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - J Cliff
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - D Errington
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - A Hall
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - C Hart
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - Z Malik
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - R Sripadam
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - H Innes
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - H Flint
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - G Langton
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - E Ahmed
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
| | - R Jackson
- Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool
| | - C Palmieri
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool.
| |
Collapse
|
3
|
Monte AA, Vest A, Reisz JA, Berninzoni D, Hart C, Dylla L, D'Alessandro A, Heard KJ, Wood C, Pattee J. Correction to: A Multi-Omic Mosaic Model of Acetaminophen Induced Alanine Aminotransferase Elevation. J Med Toxicol 2023; 19:416. [PMID: 37365428 PMCID: PMC10522543 DOI: 10.1007/s13181-023-00957-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/28/2023] Open
Affiliation(s)
- Andrew A Monte
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7Th Floor Campus Box B-215, 12401 E. 17Th Avenue, Aurora, CO, 80045, USA.
- Center for Bioinformatics & Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- Skaggs School of Pharmacy, University of Colorado, Aurora, CO, USA.
- Rocky Mountain Poison & Drug Safety, Denver Health & Hospital Authority, Denver, CO, USA.
| | - Alexis Vest
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7Th Floor Campus Box B-215, 12401 E. 17Th Avenue, Aurora, CO, 80045, USA
| | - Julie A Reisz
- Metabolomics Core, Department of Biochemistry and Molecular Genetics, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Danielle Berninzoni
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7Th Floor Campus Box B-215, 12401 E. 17Th Avenue, Aurora, CO, 80045, USA
| | - Claire Hart
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7Th Floor Campus Box B-215, 12401 E. 17Th Avenue, Aurora, CO, 80045, USA
| | - Layne Dylla
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7Th Floor Campus Box B-215, 12401 E. 17Th Avenue, Aurora, CO, 80045, USA
- Center for Bioinformatics & Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Angelo D'Alessandro
- Metabolomics Core, Department of Biochemistry and Molecular Genetics, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Kennon J Heard
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7Th Floor Campus Box B-215, 12401 E. 17Th Avenue, Aurora, CO, 80045, USA
- Rocky Mountain Poison & Drug Safety, Denver Health & Hospital Authority, Denver, CO, USA
| | - Cheyret Wood
- Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Jack Pattee
- Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| |
Collapse
|
4
|
Monte AA, Vest A, Reisz JA, Berninzoni D, Hart C, Dylla L, D'Alessandro A, Heard KJ, Wood C, Pattee J. A Multi-Omic Mosaic Model of Acetaminophen Induced Alanine Aminotransferase Elevation. J Med Toxicol 2023; 19:255-261. [PMID: 37231244 PMCID: PMC10212224 DOI: 10.1007/s13181-023-00951-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 05/13/2023] [Accepted: 05/18/2023] [Indexed: 05/27/2023] Open
Abstract
BACKGROUND Acetaminophen (APAP) is the most common cause liver injury following alcohol in US patients. Predicting liver injury and subsequent hepatic regeneration in patients taking therapeutic doses of APAP may be possible using new 'omic methods such as metabolomics and genomics. Multi'omic techniques increase our ability to find new mechanisms of injury and regeneration. METHODS We used metabolomic and genomic data from a randomized controlled trial of patients administered 4 g of APAP per day for 14 days or longer with blood samples obtained at 0 (baseline), 4, 7, 10, 13 and 16 days. We used the highest ALT as the clinical outcome to be predicted in our integrated analysis. We used penalized regression to model the relationship between genetic variants and day 0 metabolite level, and then performed a metabolite-wide colocalization scan to associate the genetically regulated component of metabolite expression with ALT elevation. Genome-wide association study (GWAS) analyses were conducted for ALT elevation and metabolite level using linear regression, with age, sex, and the first five principal components included as covariates. Colocalization was tested via a weighted sum test. RESULTS Out of the 164 metabolites modeled, 120 met the criteria for predictive accuracy and were retained for genetic analyses. After genomic examination, eight metabolites were found to be under genetic control and predictive of ALT elevation due to therapeutic acetaminophen. The metabolites were: 3-oxalomalate, allantoate, diphosphate, L-carnitine, L-proline, maltose, and ornithine. These genes are important in the tricarboxylic acid cycle (TCA), urea breakdown pathway, glutathione production, mitochondrial energy production, and maltose metabolism. CONCLUSIONS This multi'omic approach can be used to integrate metabolomic and genomic data allowing identification of genes that control downstream metabolites. These findings confirm prior work that have identified mitochondrial energy production as critical to APAP induced liver injury and have confirmed our prior work that demonstrate the importance of the urea cycle in therapeutic APAP liver injury.
Collapse
Affiliation(s)
- Andrew A Monte
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA.
- Center for Bioinformatics & Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- Skaggs School of Pharmacy, University of Colorado, Aurora, CO, USA.
- Denver Health and Hospital Authority, Rocky Mountain Poison & Drug Center, Denver, CO, USA.
| | - Alexis Vest
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA
| | - Julie A Reisz
- Metabolomics Core, Department of Biochemistry and Molecular Genetics, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Danielle Berninzoni
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA
| | - Claire Hart
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA
| | - Layne Dylla
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA
- Center for Bioinformatics & Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Angelo D'Alessandro
- Metabolomics Core, Department of Biochemistry and Molecular Genetics, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Kennon J Heard
- Department of Emergency Medicine, University of Colorado School of Medicine, Leprino Building, 7th Floor Campus Box B-215, 12401 E. 17th Avenue, Aurora, CO, 80045, USA
- Denver Health and Hospital Authority, Rocky Mountain Poison & Drug Center, Denver, CO, USA
| | - Cheyret Wood
- Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Jack Pattee
- Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA
| |
Collapse
|
5
|
Wolf CM, Zenker M, Boleti O, Norrish G, Russell M, Meisner JK, Peng DM, Prendiville T, Kleinmahon J, Kantor P, Gottlieb SD, Human D, Ewert P, Krueger M, Reber D, Donner B, Hart C, Komazec IO, Rupp S, Hahn A, Hanser A, Draaisma JM, Ten CF, Mussa A, Ferrero GB, Vaujois L, Raboisson MJ, Marquis C, Théoret Y, Bogarapu S, Dancea A, Moller HM, Kemna M, Kaski JP, Gelb BD, Andelfinger G. MAPK and mTOR Inhibition Improves Childhood RASopathy-Associated Hypertrophic Cardiomyopathy. Thorac Cardiovasc Surg 2023. [DOI: 10.1055/s-0043-1761854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023]
Affiliation(s)
- C. M. Wolf
- German Heart Center Munich, Technical University Munich, Munich, Deutschland
| | - M. Zenker
- Institute of Human Genetics and University Children's Hospital, Magdeburg, Deutschland
| | - O. Boleti
- Centre for Inherited Cardiovascular Diseases, Institute of Cardiovascular Science, London, United Kingdom
| | - G. Norrish
- Centre for Inherited Cardiovascular Diseases, Institute of Cardiovascular Science, London, United Kingdom
| | - M. Russell
- University of Michigan, Michigan, United States
| | | | - D. M. Peng
- University of Michigan, Michigan, United States
| | | | - J. Kleinmahon
- Ochsner Hospital for Children, New Orleans, United States
| | - P. Kantor
- Children's Hospital Los Angeles, Los Angeles, United States
| | - S. D. Gottlieb
- Johns Hopkins School of Medicine, Baltimore, United States
| | - D. Human
- British Columbia's Children's Hospital, Vancouver, Canada
| | - P. Ewert
- German Heart Center Munich, Technical University Munich, Munich, Deutschland
| | - M. Krueger
- Municipal Hospital Munich Schwabing, Munich, Deutschland
| | - D. Reber
- Municipal Hospital Munich Schwabing, Munich, Deutschland
| | - B. Donner
- University Children's Hospital of Basel, Basel, Switzerland
| | - C. Hart
- University of Bonn, Bonn, Deutschland
| | | | - S. Rupp
- University of Giessen and Marburg, Giessen, Deutschland
| | - A. Hahn
- University of Giessen, Giessen, Deutschland
| | - A. Hanser
- University Hospital Tübingen, Eberhard-Karls University Tübingen, Tübingen, Deutschland
| | - J. M. Draaisma
- Radboud University Medical Center, Nijmegen, Netherlands
| | - C. F.E. Ten
- Radboud University Medical Center, Nijmegen, Netherlands
| | - A. Mussa
- University of Torino, Torino, Italy
| | | | | | | | - C. Marquis
- Université de Montréal, Montreal, Canada
| | - Y. Théoret
- Université de Montréal, Montreal, Canada
| | - S. Bogarapu
- University of Illinois College of Medicine, Peoria, United States
| | - A. Dancea
- McGill University Health Center, Montreal, Canada
| | | | - M. Kemna
- Seattle Children´s Hospital, Seattle, United States
| | - J. P. Kaski
- Centre for Inherited Cardiovascular Diseases, Institute of Cardiovascular Science, London, United Kingdom
| | - B. D. Gelb
- Icahn School of Medicine at Mount Sinai, New York, United States
| | | |
Collapse
|
6
|
Gumus M, Sukalinskaya A, Andric Z, Cheshuk V, Ciuleanu TE, Sezgin Goksu S, Cil T, Cicin I, Bulat I, Ostapenko Y, Penkov K, Hart C, Lai M, Chaao B, Jimenez J, Sepahi A, Shi G, Trott S, Hooper E. 181P SELECT: A phase II randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
7
|
Andelfinger G, Zenker M, Norrish G, Russell M, Meisner J, Peng D, Prendiville T, Kleinmahon J, Kantor P, Sen DG, Human D, Ewert P, Krueger M, Reber D, Donner B, Hart C, Odri-Komazec I, Rupp S, Hahn A, Hanser A, Hofbeck M, Draaisma J, Udink ten Cate F, Mussa A, Ferrero G, Vaujois L, Raboisson M, Delrue M, Marquis C, Théorêt Y, Kaski J, Gelb B, Wolf C. MAPK AND AKT/MTOR INHIBITION IMPROVES CHILDHOOD RASOPATHY-ASSOCIATED CARDIOMYOPATHY. Can J Cardiol 2022. [DOI: 10.1016/j.cjca.2022.08.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Kravchenko D, Isaak A, Mesropyan N, Endler C, Bischoff L, Vollbrecht T, Pieper C, Sedaghat A, Kütting D, Hart C, Feißt A, Attenberger U, Luetkens J. Kardio MRT bei Verdacht auf akute Myokarditis nach mRNA COVID-19 Impfung. ROFO-FORTSCHR RONTG 2022. [DOI: 10.1055/s-0042-1749810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | - A Isaak
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - N Mesropyan
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - C Endler
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - L Bischoff
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - T Vollbrecht
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - C Pieper
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - A Sedaghat
- Uniklinik Bonn, Klinik für innere Medizin II – Kardiologie, Bonn
| | - D Kütting
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - C Hart
- Uniklinik Bonn, Kinderkardiologie, Bonn
| | - A Feißt
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - U Attenberger
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| | - J Luetkens
- Uniklinik Bonn, Klinik für diagnostische und interventionelle Radiologie, Bonn
| |
Collapse
|
9
|
Vollbrecht T, Hart C, Herberg U, Katemann C, Zhang S, Isaak A, Mesropyan N, Kravchenko D, Bischoff ML, Pieper CC, Kütting D, Faridi B, Attenberger U, Geipel A, Luetkens AJ. Doppler-Ultraschall (DUS)-getriggerte fetale Herz-MRT zur Diagnose komplexer Herzfehler bei 3 Tesla: Klinische Etablierung und diagnostische Wertigkeit. ROFO-FORTSCHR RONTG 2022. [DOI: 10.1055/s-0042-1749889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- T Vollbrecht
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - C Hart
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - U Herberg
- Uniklinikum Bonn, Abteilung für Kinderkardiologie, Bonn
| | | | - S Zhang
- Philips GmbH Market DACH, Hamburg
| | - A Isaak
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - N Mesropyan
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - D Kravchenko
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - M L Bischoff
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - C C Pieper
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - D Kütting
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - B Faridi
- Uniklinikum Bonn, Abteilung für Geburtshilfe und Pränatalmedizin, Bonn
| | - U Attenberger
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - A Geipel
- Uniklinikum Bonn, Abteilung für Geburtshilfe und Pränatalmedizin, Bonn
| | - A J Luetkens
- Uniklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| |
Collapse
|
10
|
Isaak A, Mesropyan N, Hart C, Kravchenko D, Endler C, Bischoff L, Zhang S, Katemann C, Weber O, Kuetting D, Attenberger U, Dabir D, Luetkens J. Kontrastmittelfreie REACT MRA unter freier Atmung zur Beurteilung der thorakalen Gefäße bei Kleinkindern mit angeborenen Herzfehlern. ROFO-FORTSCHR RONTG 2022. [DOI: 10.1055/s-0042-1749795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A Isaak
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - N Mesropyan
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - C Hart
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Zentrum für Kinderheilkunde/Abteilung für Kinderkardiologie, Bonn
| | - D Kravchenko
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - C Endler
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - L Bischoff
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - S Zhang
- Philips GmbH Market DACH, Hamburg
| | | | - O Weber
- Philips GmbH Market DACH, Hamburg
| | - D Kuetting
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - U Attenberger
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - D Dabir
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| | - J Luetkens
- Universitätsklinikum Bonn, Klinik für Diagnostische und Interventionelle Radiologie, Bonn
| |
Collapse
|
11
|
Hart C, Shadbolt L, Kaklamanos M. 999 ACUTE FRAILTY ASSESSMENT UNIT: A 6-MONTH QUALITATIVE STUDY OF READMISSIONS WITHIN 28 DAYS OF DISCHARGE & COLLECTIVE CASE ANALYSIS. Age Ageing 2022. [DOI: 10.1093/ageing/afac126.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Readmissions can have a negative impact on the care of frail individuals in regards to increased length of stay, healthcare-related harm, reduced quality of life and mortality. Review of frailty readmissions should lead to improvements of frailty care and clinical effectiveness.
Method
We conducted a retrospective, qualitative analysis of readmissions of frail individuals discharged from our Acute Frailty Unit (AFU) over a six-month period. This is a collective case study in which we used instrumental cases to highlight specific learning points. We used the Electronic Patient Records database to measure the total number of readmissions related to AFU discharges. The Framework methodology was then utilised to further analyse and cluster cases. Common themes linked to readmissions and the time-to-readmission were studied, leading to structured (SMART) quality improvement interventions.
Results
Four hundred and thirty individuals were discharged from AFU. Eighty-nine (21%) were readmitted within 28 days of index hospital admission. Fifty-eight percent (50/89) of individuals were readmitted to hospital (any ward) with a different presenting complaint compared to index admission. Twenty-two (25%) cases were readmitted with the same initial complaint, while nine (10%) experienced problems due to ineffective discharge planning. In eight (7%) cases, readmission was linked to healthcare-associated complications. Forty (45%,40/89) individuals stayed at home for <7 days after their index discharge, whilst the remaining forty-nine (55%) returned to hospital after 7–28 days. Only eight (9%) readmissions were from care home settings. A bundle of SMART interventions has been developed, including post-discharge support with acute frailty clinics, enhanced frailty dietetic support and improved communication with community partners.
Conclusion
(s) This collective case study shares important learnings related to the readmission patterns of acute frailty units. Individual case studies are essential in understanding the ways that patient-centred care should be tailored to become more effective.
Collapse
Affiliation(s)
- C Hart
- Frailty Team, East Kent Hospitals University Foundation Trust, Queen Elizabeth the Queen Mother Hospital , Margate, Kent
| | - L Shadbolt
- Frailty Team, East Kent Hospitals University Foundation Trust, Queen Elizabeth the Queen Mother Hospital , Margate, Kent
| | - M Kaklamanos
- Frailty Team, East Kent Hospitals University Foundation Trust, Queen Elizabeth the Queen Mother Hospital , Margate, Kent
| |
Collapse
|
12
|
Nagarkar M, Keely SP, Jahne M, Wheaton E, Hart C, Smith B, Garland J, Varughese EA, Braam A, Wiechman B, Morris B, Brinkman NE. SARS-CoV-2 monitoring at three sewersheds of different scales and complexity demonstrates distinctive relationships between wastewater measurements and COVID-19 case data. Sci Total Environ 2022; 816:151534. [PMID: 34780821 PMCID: PMC8590472 DOI: 10.1016/j.scitotenv.2021.151534] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 11/04/2021] [Accepted: 11/04/2021] [Indexed: 05/18/2023]
Abstract
Wastewater monitoring of SARS-CoV-2 presents a means of tracking COVID-19 community infection dynamics on a broader geographic scale. However, accounting for environmental and sample-processing losses may be necessary for wastewater measurements to readily inform our understanding of infection prevalence. Here, we present measurements of the SARS-CoV-2 N1 and N2 gene targets from weekly wastewater samples at three sites in Hamilton County, Ohio, during an increase and subsequent decline of COVID-19 infections. The concentration of N1 or N2 RNA in wastewater, measured over the course of six months, ranged from below the detection limit to over 104 gene copies/l, and correlated with case data at two wastewater treatment plants, but not at a sub-sewershed-level sampling site. We also evaluated the utility of a broader range of variables than has been reported consistently in previous work, in improving correlations of SARS-CoV-2 concentrations with case data. These include a spiked matrix recovery control (OC43), flow-normalization, and assessment of fecal loading using endogenous fecal markers (HF183, PMMoV, crAssphage). We found that adjusting for recovery, flow, and fecal indicators increased these correlations for samples from a larger sewershed (serving ~488,000 people) with greater industrial and stormwater inputs, but raw N1/N2 concentrations corresponded better with case data at a smaller, residential-oriented sewershed. Our results indicate that the optimal adjustment factors for correlating wastewater and clinical case data moving forward may not be generalizable to all sewersheds.
Collapse
Affiliation(s)
- M Nagarkar
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - S P Keely
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - M Jahne
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - E Wheaton
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - C Hart
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - B Smith
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - J Garland
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - E A Varughese
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - A Braam
- APTIM Corp., 4171 Essen Lane, Baton Rouge, LA 70809.
| | - B Wiechman
- APTIM Corp., 4171 Essen Lane, Baton Rouge, LA 70809.
| | - B Morris
- Pegasus Technical Services Inc., 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| | - N E Brinkman
- Office of Research and Development, United States Environmental Protection Agency, 26 W Martin Luther King Dr, Cincinnati, OH, USA.
| |
Collapse
|
13
|
Wolf CM, Zenker M, Norrish G, Russell M, Meisner JK, Peng DM, Prendiville T, Kleinmahon J, Kantor PF, Sen DG, Human DG, Ewert P, Krueger M, Reber D, Donner BC, Hart C, Odri-Komazec I, Rupp S, Hahn A, Hanser A, Hofbeck M, Draaisma JM, Cate FUT, Mussa A, Ferrero GB, Marquis C, Théoret Y, Kaski JP, Gelb BD, Andelfinger G. AKT/mTOR and MAPK Inhibition Improves Childhood RASopathic Cardiomyopathy. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - M. Zenker
- Institute of Human Genetics and Applied Genomics, Magdeburg, Deutschland
| | | | - M. Russell
- University of Michigan, Michigan, United States
| | | | - D. M. Peng
- University of Michigan, Michigan, United States
| | | | - J. Kleinmahon
- Ochsner Hospital for Children, New Orleans, United States
| | - P. F. Kantor
- Children's Hospital Los Angeles, Los Angeles, United States
| | | | - D. G. Human
- British Columbia's Children's Hospital, Vancouver, Canada
| | - P. Ewert
- Lazarettstr. 36, München, Deutschland
| | - M. Krueger
- Department of Neonatology, Municipal Hospital Munich Schwabing, Munich, Deutschland
| | - D. Reber
- Department of Neonatology, Municipal Hospital Munich Schwabing, Munich, Deutschland
| | - B. C. Donner
- Pediatric Cardiology, University Children's Hospital of Basel (UKBB), University of Basel, Basel, Switzerland
| | - C. Hart
- Paediatric Heart Center, Children's Hospital, University of Bonn, Bonn, Deutschland
| | | | - S. Rupp
- Launsbacher Straße 29a, Gießen, Deutschland
| | - A. Hahn
- Kinderklinik Gießen, Gießen, Deutschland
| | - A. Hanser
- Hoppe-Seyler-Str. 1, Tübingen, Deutschland
| | - M. Hofbeck
- Hoppe-Seyler-Str. 1, Tübingen, Deutschland
| | - J. M. Draaisma
- Radboud Institute for Health Sciences, Amalia Children's Hospital, Nijmegen, The Netherlands
| | - F.E.A. Udink Ten Cate
- Radboud Institute for Health Sciences, Amalia Children's Hospital, Nijmegen, The Netherlands
| | - A. Mussa
- Department of Public Health and Pediatric Sciences, University of Torino, Torino, Italy
| | - G. B. Ferrero
- Department of Clinical and Biological Sciences, School of Medicine, University of Torino, Torino, Italy
| | - C. Marquis
- Department of Pediatrics, CHU Sainte Justine, Université de Montréal, Montreal, Canada
| | - Y. Théoret
- Department of Pediatrics, CHU Sainte Justine, Université de Montréal, Montreal, Canada
| | - J. P. Kaski
- FRCP, Centre for Inherited Cardiovascular Diseases, Institute of Cardiovascular Science, London, United Kingdom
| | - B. D. Gelb
- Icahn School of Medicine at Mount Sinai, New York, United States
| | - G. Andelfinger
- Cardiovascular Genetics, CHU Sainte Justine, Université de Montreal, Montreal, Canada
| |
Collapse
|
14
|
Angamuthu N, Gilliland J, Chowdhury S, D'Souza R, Hart C, Knowles J. 293 A Reflection of Experience Gained in Emergency General Surgery During The COVID-19 Pandemic at A London University Hospital. Br J Surg 2021. [PMCID: PMC8524542 DOI: 10.1093/bjs/znab259.450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Background During COVID-19, acute surgical services witnessed an overhaul of practice due to constraints on staff and resource (beds, imaging, and theater) availability. Fear of COVID-19, among general population potentially added to delay in patients seeking medical assistance. This study describes experiences of acute general surgery at a COVID-19 designated tertiary institution wherein elective surgical work was put on hold and emergency on-call rota was modified during the pandemic. Method A retrospective analysis (March-April 2019 vs 2020) of the surgical work from a prospectively maintained surgical database during COVID-19 was performed. Results Emergency surgical admissions during March 2020 vs 2019 was 106 vs 207. Comparing the workload March-April 2020 vs 2019, emergency referrals were 266 vs 341, operations performed 71 vs 92. 31.5% (84/266) of patients were tested for COVID and 30% (25/84) were positive. Emergency surgery was performed in 71 patients (including appendectomies (28), hernia repair(3), laparotomy(3), Hartman’s procedure(3), hemicolectomy(7) and anterior resection with covering ileostomy(2)). In this group, a male preponderance was noted (M:F 1.84:1), the average age was 43.2 years (6-91), length of stay 4.8 days (<23 hours-34 days). In the operative group, the 30-day mortality was 4.23% (3/71) and the morbidity was 31%. Conclusions With local changes, stopping elective services, modifying on-call rota, a surgical department can continue to be functional and offer emergency surgical service for a sustained period during a pandemic. During the COVID pandemic, the average number of referrals, admissions and surgeries were lower when compared to the non-covid period.
Collapse
Affiliation(s)
| | | | | | - R D'Souza
- Royal Free Hospital, London, United Kingdom
| | - C Hart
- Royal Free Hospital, London, United Kingdom
| | - J Knowles
- Royal Free Hospital, London, United Kingdom
| |
Collapse
|
15
|
Hart C, Freeman H, Jones I, Turer R. 259 Improving Emergency Medicine Order Effectiveness: A Comprehensive Revision of the "Quick List” Order Model. Ann Emerg Med 2021. [DOI: 10.1016/j.annemergmed.2021.09.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Lehane M, Connolly S, Crowley M, Hart C, O"flynn AM. Kidney function decline in heart failure patients: an audit of out-patient heart failure services. Eur J Cardiovasc Nurs 2021. [DOI: 10.1093/eurjcn/zvab060.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
A bidirectional relationship exists between the kidney and the heart; the lower the eGFR the more challenging it is to manage the heart failure (HF) patient. Worsening renal function is common in HF patients and associated with a two-fold increase in mortality and a lower likelihood of being prescribed efficacious HF therapy. The role of cardio-renal interactions in HF is essential to identify risk and subsequent treatment strategies.
Purpose
The purpose of this audit is to provide insights into the assessment of renal function in a real world heart failure population by identifying the degree of renal dysfunction and changes in renal function over a five year time frame.
Methods
A retrospective audit included patients with HFrEF attending a heart failure service. These patients were classified using KIDGO criteria CKD 1-5. A current eGFR sample was compared with a sample taken five years earlier, identified using the electronic laboratory record. Ethical approval was granted from the Research Ethics Committee.
Resultss
100 patients with HFrEF attending a heart failure service fulfilled the selection criteria of which sixty three patients with an eGFR >60ml/min/1.73 m2 were audited. Of this group 43 were CKD class 2 and 20 were CKD class 1. Thirty seven patients had an eGFR <60ml/min/1.73 m2 of which 9 were class 3b, 9 were CKD class 4 and 1 was CKD Class 5.
Of the 100 patients enrolled, 6 were excluded from the analysis of kidney function decline as an eGFR from five years earlier was unavailable. Within a five year time span, 44 patients did not change their CKD class, 31 patients declined by one class, 9 patients declined by two classes, 3 patients declined by three classes and 7 patients improved their kidney function.
GFR < 60mL/min/1.73m2,
n = 37
GFR > 60mL/min/1.73m2, n = 63
Age – mean (range)
77.8 (49-94)
66.5 (45-89)
Gender – female (%)
12 (32%)
16 (25%)
Average renal function measurements (mean, range)
6.4
6.7
Total albumin
creatinine ratio measurements
8
6
Actively attending renal service
6
0
Conclusion
Nurses should be aware of the increasing risk conferred by the dual diagnosis of heart failure and chronic kidney disease. Patients with heart failure who have decreasing eGFR levels (especially less than 30 mL/min), should have collaborative management with nephrology services to optimise outcomes. Recognition of CKD in our institution and referral to nephrology services was suboptimal and further work is necessary to optimise the management of these patients.
Collapse
Affiliation(s)
- M Lehane
- Mallow General Hospital, Heart Failure Unit, Cork, Ireland
| | - S Connolly
- Mallow General Hospital, Heart Failure Unit, Cork, Ireland
| | - M Crowley
- Mallow General Hospital, Heart Failure Unit, Cork, Ireland
| | - C Hart
- Mallow General Hospital, Heart Failure Unit, Cork, Ireland
| | - AM O"flynn
- Mallow General Hospital, Heart Failure Unit, Cork, Ireland
| |
Collapse
|
17
|
Brown M, Hart C, Sachdeva A, Oliveira P, Frankhauser C, Wedge D, Clarke N. Localised activation of the EMT switch by peri–neural invading epithelial cells in prostate cancer. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00810-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Sueblinvong V, Chang S, Park C, Benza R, Archer D, Sutliff R, Hart C, Kang B. Circular RNA Expression in the Lungs of Sickle Cell Disease Mice. FASEB J 2021. [DOI: 10.1096/fasebj.2021.35.s1.03765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Sarah Chang
- MedicineEmory UniversityAtlantaGA
- Emory UniversityAtlantaGA
| | - Changwon Park
- Cellular and Molecular PhysiologyLouisiana State University Health Science CenterShreveportLA
| | | | | | | | | | - Bum‐Yong Kang
- MedicineEmory UniversityAtlantaGA
- Emory UniversityAtlantaGA
| |
Collapse
|
19
|
Wong PM, Barker DH, Raynor HA, Hart C, Carskadon MA. 0257 Preliminary Findings: Attentional Bias for Food Cues Unrelated to Time Awake or Circadian Phase During Forced Desynchrony in Adolescents. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Sleep quantity and quality influence attentional bias, and attentional bias for food cues has been associated with body weight. Whether the endogenous circadian cycle and/or time from awakening to bedtime contribute to attentional bias for food and differences in weight remain unclear. Using a 28-h forced desynchrony (FD) design, we hypothesized that adolescents with overweight (OW) and obesity (O) would have more attentional bias for food cues later in the wake episode and at a later circadian phase compared to adolescents with a healthy weight (HW).
Methods
50 (28 male) adolescents (12-15yr) completed 7 FD cycles. Participants completed an attentional bias task that included three food word categories (savory, sweet, fruits/vegetables) and one non-food word category (school supplies). The task was completed at 6 fixed times each cycle: Task 1 was 1.3h after scheduled awaking, Task 2 was 2h after Task 1, and Tasks 3–6 followed at 3-h intervals. Weight categorization used body mass index (BMI) percentiles (CDC): HW (>5th and <85th; n=24), OW (85th and <95th; n=13), or O (≥95th; n=14). Endogenous circadian period was determined using salivary melatonin onsets (Mean: HW=23.88h; OW=24.01h; O=23.86h). Effect of circadian phase and time since scheduled awakening was assessed by mixed effects modeling using 6 circadian and 6 time-awake bins.
Results
We found no significant differences between weight groups in attentional bias for any of the food categories (p’s >.05). We also saw no significant time awake effects or circadian influence on attentional bias, nor did time awake or circadian phase moderate the associations between weight category and attentional bias (p’s >.05).
Conclusion
Weight groups did not impact food-related attentional bias across the wake episode or circadian phase. Future directions will explore whether attentional bias for food types predicts food choice and food consumption in this study.
Support
DK101046
Collapse
Affiliation(s)
- P M Wong
- Department of Psychology, University of Pittsburgh, Pittsburgh, PA
| | - D H Barker
- Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, RI
| | - H A Raynor
- Department of Nutrition, University of Tennessee, Knoxville, TN
| | - C Hart
- Department of Public Health, Temple University, Philadelphia, PA
| | - M A Carskadon
- Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, RI
| |
Collapse
|
20
|
Carskadon M, Barker D, Hart C, Raynor H, Mason I, Scheer F. Caloric intake in normal weight, overweight, and obese adolescents: circadian and homeostatic influences measured from 28-hour forced desynchrony (FD). Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, Simões BM, Lefley D, Tulotta C, Storer J, Gurney A, Clarke N, Brown M, Howell SJ, Sims AH, Farnie G, Ottewell PD, Clarke RB. Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat Commun 2019; 10:5016. [PMID: 31676788 PMCID: PMC6825219 DOI: 10.1038/s41467-019-12807-0] [Citation(s) in RCA: 92] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Accepted: 10/02/2019] [Indexed: 02/07/2023] Open
Abstract
Dissemination of tumour cells to the bone marrow is an early event in breast cancer, however cells may lie dormant for many years before bone metastases develop. Treatment for bone metastases is not curative, therefore new adjuvant therapies which prevent the colonisation of disseminated cells into metastatic lesions are required. There is evidence that cancer stem cells (CSCs) within breast tumours are capable of metastasis, but the mechanism by which these colonise bone is unknown. Here, we establish that bone marrow-derived IL1β stimulates breast cancer cell colonisation in the bone by inducing intracellular NFkB and CREB signalling in breast cancer cells, leading to autocrine Wnt signalling and CSC colony formation. Importantly, we show that inhibition of this pathway prevents both CSC colony formation in the bone environment, and bone metastasis. These findings establish that targeting IL1β-NFKB/CREB-Wnt signalling should be considered for adjuvant therapy to prevent breast cancer bone metastasis.
Collapse
Affiliation(s)
- Rachel Eyre
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - Denis G Alférez
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - Angélica Santiago-Gómez
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - Kath Spence
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - James C McConnell
- Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchester, M13 9PT, UK
| | - Claire Hart
- Genito Urinary Cancer Research Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - Bruno M Simões
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - Diane Lefley
- Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, S10 2RX, UK
| | - Claudia Tulotta
- Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, S10 2RX, UK
| | - Joanna Storer
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - Austin Gurney
- OncoMed Pharmaceuticals, Redwood City, CA, 94063, USA
| | - Noel Clarke
- Department of Urology, Salford Royal Hospital NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK
| | - Mick Brown
- Genito Urinary Cancer Research Group, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
| | - Sacha J Howell
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK
- The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK
| | - Andrew H Sims
- Applied Bioinformatics of Cancer Group, Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XR, UK
| | - Gillian Farnie
- Structural Genomics Consortium, NDORMS, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK
| | - Penelope D Ottewell
- Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, S10 2RX, UK.
| | - Robert B Clarke
- Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Wilmslow Road, Manchester, M20 4GJ, UK.
| |
Collapse
|
22
|
|
23
|
Gnatiuc L, Herrington WG, Halsey J, Tuomilehto J, Fang X, Kim HC, De Bacquer D, Dobson AJ, Criqui MH, Jacobs DR, Leon DA, Peters SAE, Ueshima H, Sherliker P, Peto R, Collins R, Huxley RR, Emberson JR, Woodward M, Lewington S, Aoki N, Arima H, Arnesen E, Aromaa A, Assmann G, Bachman DL, Baigent C, Bartholomew H, Benetos A, Bengtsson C, Bennett D, Björkelund C, Blackburn H, Bonaa K, Boyle E, Broadhurst R, Carstensen J, Chambless L, Chen Z, Chew SK, Clarke R, Cox C, Curb JD, D'Agostino R, Date C, Davey Smith G, De Backer G, Dhaliwal SS, Duan XF, Ducimetiere P, Duffy S, Eliassen H, Elwood P, Empana J, Garcia-Palmieri MH, Gazes P, Giles GG, Gillis C, Goldbourt U, Gu DF, Guasch-Ferre M, Guize L, Haheim L, Hart C, Hashimoto S, Hashimoto T, Heng D, Hjermann I, Ho SC, Hobbs M, Hole D, Holme I, Horibe H, Hozawa A, Hu F, Hughes K, Iida M, Imai K, Imai Y, Iso H, Jackson R, Jamrozik K, Jee SH, Jensen G, Jiang CQ, Johansen NB, Jorgensen T, Jousilahti P, Kagaya M, Keil J, Keller J, Kim IS, Kita Y, Kitamura A, Kiyohara Y, Knekt P, Knuiman M, Kornitzer M, Kromhout D, Kronmal R, Lam TH, Law M, Lee J, Leren P, Levy D, Li YH, Lissner L, Luepker R, Luszcz M, MacMahon S, Maegawa H, Marmot M, Matsutani Y, Meade T, Morris J, Morris R, Murayama T, Naito Y, Nakachi K, Nakamura M, Nakayama T, Neaton J, Nietert PJ, Nishimoto Y, Norton R, Nozaki A, Ohkubo T, Okayama A, Pan WH, Puska P, Qizilbash N, Reunanen A, Rimm E, Rodgers A, Saitoh S, Sakata K, Sato S, Schnohr P, Schulte H, Selmer R, Sharp D, Shifu X, Shimamoto K, Shipley M, Silbershatz H, Sorlie P, Sritara P, Suh I, Sutherland SE, Sweetnam P, Tamakoshi A, Tanaka H, Thomsen T, Tominaga S, Tomita M, Törnberg S, Tunstall-Pedoe H, Tverdal A, Ueshima H, Vartiainen E, Wald N, Wannamethee SG, Welborn TA, Whincup P, Whitlock G, Willett W, Woo J, Wu ZL, Yao SX, Yarnell J, Yokoyama T, Yoshiike N, Zhang XH. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol 2018; 6:538-546. [PMID: 29752194 PMCID: PMC6008496 DOI: 10.1016/s2213-8587(18)30079-2] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 02/20/2018] [Accepted: 02/26/2018] [Indexed: 01/06/2023]
Abstract
BACKGROUND Several studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether differences in established risk factors, such as blood pressure, BMI, smoking, and cholesterol, explain the higher relative risks of vascular mortality among women than among men. METHODS In our meta-analysis, we obtained individual participant-level data from studies included in the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration that had obtained baseline information on age, sex, diabetes, total cholesterol, blood pressure, tobacco use, height, and weight. Data on causes of death were obtained from medical death certificates. We used Cox regression models to assess the relevance of diabetes (any type) to occlusive vascular mortality (ischaemic heart disease, ischaemic stroke, or other atherosclerotic deaths) by age, sex, and other major vascular risk factors, and to assess whether the associations of blood pressure, total cholesterol, and body-mass index (BMI) to occlusive vascular mortality are modified by diabetes. RESULTS Individual participant-level data were analysed from 980 793 adults. During 9·8 million person-years of follow-up, among participants aged between 35 and 89 years, 19 686 (25·6%) of 76 965 deaths were attributed to occlusive vascular disease. After controlling for major vascular risk factors, diabetes roughly doubled occlusive vascular mortality risk among men (death rate ratio [RR] 2·10, 95% CI 1·97-2·24) and tripled risk among women (3·00, 2·71-3·33; χ2 test for heterogeneity p<0·0001). For both sexes combined, the occlusive vascular death RRs were higher in younger individuals (aged 35-59 years: 2·60, 2·30-2·94) than in older individuals (aged 70-89 years: 2·01, 1·85-2·19; p=0·0001 for trend across age groups), and, across age groups, the death RRs were higher among women than among men. Therefore, women aged 35-59 years had the highest death RR across all age and sex groups (5·55, 4·15-7·44). However, since underlying confounder-adjusted occlusive vascular mortality rates at any age were higher in men than in women, the adjusted absolute excess occlusive vascular mortality associated with diabetes was similar for men and women. At ages 35-59 years, the excess absolute risk was 0·05% (95% CI 0·03-0·07) per year in women compared with 0·08% (0·05-0·10) per year in men; the corresponding excess at ages 70-89 years was 1·08% (0·84-1·32) per year in women and 0·91% (0·77-1·05) per year in men. Total cholesterol, blood pressure, and BMI each showed continuous log-linear associations with occlusive vascular mortality that were similar among individuals with and without diabetes across both sexes. INTERPRETATION Independent of other major vascular risk factors, diabetes substantially increased vascular risk in both men and women. Lifestyle changes to reduce smoking and obesity and use of cost-effective drugs that target major vascular risks (eg, statins and antihypertensive drugs) are important in both men and women with diabetes, but might not reduce the relative excess risk of occlusive vascular disease in women with diabetes, which remains unexplained. FUNDING UK Medical Research Council, British Heart Foundation, Cancer Research UK, European Union BIOMED programme, and National Institute on Aging (US National Institutes of Health).
Collapse
|
24
|
Domenyuk V, Liu X, Magee D, Gatalica Z, Stark A, Kennedy P, Rosenow M, Barker A, Berry D, Poste G, Halbert D, Hart C, Famulok M, Mayer G, Korn M, Miglarese M, Spetzler D. Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG. Lipid degradation promotes prostate cancer cell survival. Oncotarget 2018; 8:38264-38275. [PMID: 28415728 PMCID: PMC5503531 DOI: 10.18632/oncotarget.16123] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 03/01/2017] [Indexed: 01/07/2023] Open
Abstract
Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased ECI2 expression predicts mortality in prostate cancer patients (p = 0.0086). ECI2 encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads to decreased glucose utilization, accumulation of fatty acids and down-regulation of cell cycle related genes. In normal cells, decrease in fatty acid degradation is compensated by increased consumption of glucose, and here we demonstrate that prostate cancer cells are not able to respond to decreased fatty acid degradation. Instead, prostate cancer cells activate incomplete autophagy, which is followed by activation of the cell death response. Finally, we identified a clinically approved compound, perhexiline, which inhibits fatty acid degradation, and replicates the major findings for ECI2 knockdown. This work shows that prostate cancer cells require lipid degradation for survival and identifies a small molecule inhibitor with therapeutic potential.
Collapse
Affiliation(s)
- Harri M Itkonen
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway
| | - Michael Brown
- Genito Urinary Cancer Research Group, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom
| | - Alfonso Urbanucci
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway.,Department of Molecular Oncology, Institute for Cancer Research and Oslo University Hospital, Oslo, Norway
| | - Gregory Tredwell
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Chung Ho Lau
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Stefan Barfeld
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway
| | - Claire Hart
- Genito Urinary Cancer Research Group, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom
| | - Ingrid J Guldvik
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway
| | - Mandeep Takhar
- GenomeDx Biosciences, Vancouver, British Columbia, Canada
| | - Hannelore V Heemers
- Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio, USA.,Department of Hematology/Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Nicholas Erho
- GenomeDx Biosciences, Vancouver, British Columbia, Canada
| | - Katarzyna Bloch
- Department of Oncology, Laboratory of Lipid Metabolism and Cancer, LKI Leuven Cancer Institute, KU Leuven-University of Leuven, Leuven, Belgium
| | - Elai Davicioni
- GenomeDx Biosciences, Vancouver, British Columbia, Canada
| | - Rita Derua
- Department of Cellular and Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven-University of Leuven, Leuven, Belgium
| | - Etienne Waelkens
- Department of Cellular and Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven-University of Leuven, Leuven, Belgium
| | - James L Mohler
- Department of Urology, Roswell Park Cancer Institute, Buffalo, New York, USA
| | - Noel Clarke
- Genito Urinary Cancer Research Group, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom.,PCUK/Movember Centre of Excellence for Prostate Cancer Research, CRUK Manchester Institute for Cancer Research, University of Manchester, Manchester, UK.,Department of Urology, The Christie NHS Foundation Trust, Manchester, UK
| | - Johan V Swinnen
- Department of Oncology, Laboratory of Lipid Metabolism and Cancer, LKI Leuven Cancer Institute, KU Leuven-University of Leuven, Leuven, Belgium
| | - Hector C Keun
- Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Ole P Rekvig
- Department of Medical Biology, University of Tromso, Tromso Norway
| | - Ian G Mills
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway.,Department of Molecular Oncology, Institute for Cancer Research and Oslo University Hospital, Oslo, Norway.,PCUK/Movember Centre of Excellence for Prostate Cancer Research, Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, Belfast, UK
| |
Collapse
|
26
|
Bradley T, Hart C, Hora B, Pollara J, Browne E, Anthony Moody M, Ferrari G, Margolis D, Haynes B. High-throughput single-cell transcriptome analysis of immune cells from HIV-1 infected individuals before and after therapy. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30548-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
27
|
Rickers C, Andrade A, Jerosch-Herold M, Wegner P, Voges I, Pham M, Hart C, Gabbert D, Kristo I, Kramer H. Determinants of Left Ventricular Dysfunction and Remodeling in Patients with Corrected Tetralogy of Fallot (ToF). Thorac Cardiovasc Surg 2017. [DOI: 10.1055/s-0037-1598972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- C. Rickers
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A. Andrade
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | | | - P. Wegner
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - I. Voges
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M. Pham
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - C. Hart
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - D. Gabbert
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - I. Kristo
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - H. Kramer
- Department of Congenital Heart Disease and Paediatric Cardiology, University Hospital Schleswig-Holstein, Kiel, Germany
| |
Collapse
|
28
|
Hart C, Cock IE. An examination of the antimicrobial and anticancer properties of Garcinia cambogia fruit pericarp extracts. ACTA ACUST UNITED AC 2016. [DOI: 10.5530/bems.2016.2.10] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
29
|
Di Donato S, Mislang A, Vignoli A, Mori E, Vitale S, Biagioni C, Hart C, Becheri D, Del Monte F, Luchinat C, Di Leo A, Mottino G, Tenori L, Biganzoli L. Serum metabolomic as biomarkers to differentiate early from metastatic disease in elderly colorectal cancer (crc) patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Eyre R, Spence K, Alferez D, Santiago-Gomez A, Hart C, Simoes B, Brown M, Gurney A, Farnie G, Clarke R. The bone metastatic niche promotes breast cancer stem cell activity via IL-1β-Wnt signalling. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61224-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
31
|
Bromby A, Hart C, Brown M, Clarke N. Prognostic potential of EphA2 expression in prostate cancer patients. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61654-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Hart C, Müller M, Scheewe J, Kramer H. Sinusknotendysfunktion im Langzeitverlauf beim Hypoplastischen Linksherzsyndrom (HLHS). Thorac Cardiovasc Surg 2016. [DOI: 10.1055/s-0036-1571860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Salehi R, Attmann T, Scheewe J, Al Bulushi A, Gabbert D, Wegner P, Pardun E, Voges I, Hart C, Kristo I, Kramer H, Rickers C. The Effect of the Simultaneous Left Pulmonary Artery (LPA) Patch Enlargement during the Modified Norwood Procedure on the Lung Perfusion: First MRI Results of HLHS Patients. Thorac Cardiovasc Surg 2016. [DOI: 10.1055/s-0036-1571862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Gabbert D, Hart C, Wegner P, Jerosch-Herold M, Salehi R, Voges I, Kristo I, Al Bulushi A, Kramer HH, Rickers C. Atmung oder Herzschlag: Was sind die Blutflussbeiträge im Fontan-Tunnel? Thorac Cardiovasc Surg 2016. [DOI: 10.1055/s-0036-1571864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Wildschut T, van Horen F, Hart C. Accountability Accentuates Interindividual-Intergroup Discontinuity by Enforcing Parochialism. Front Psychol 2015; 6:1789. [PMID: 26635691 PMCID: PMC4658441 DOI: 10.3389/fpsyg.2015.01789] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Accepted: 11/06/2015] [Indexed: 11/20/2022] Open
Abstract
Interindividual-intergroup discontinuity is the tendency for relations between groups to be more competitive than relations between individuals. We examined whether the discontinuity effect arises in part because group members experience normative pressure to favor the ingroup (parochialism). Building on the notion that accountability enhances normative pressure, we hypothesized that the discontinuity effect would be larger when accountability is present (compared to absent). A prisoner's dilemma game experiment supported this prediction. Specifically, intergroup (compared to interindividual) interaction activated an injunctive ingroup-favoring norm, and accountability enhanced the influence of this norm on competitive behavior.
Collapse
Affiliation(s)
- Tim Wildschut
- Centre for Research on Self and Identity, School of Psychology, University of SouthamptonSouthampton, UK
| | - Femke van Horen
- Department of Marketing, Vrije Universiteit AmsterdamAmsterdam, Netherlands
| | - Claire Hart
- Centre for Research on Self and Identity, School of Psychology, University of SouthamptonSouthampton, UK
| |
Collapse
|
36
|
Puri K, Kocoshis S, Risma K, Perez L, Hart C, Chin C, Ryan TD, Jefferies JL, Schumacher KR, Castleberry C. Basiliximab treatment for autoimmune bowel disease in a pediatric heart transplant patient. Pediatr Transplant 2015; 19:E165-9. [PMID: 26374667 PMCID: PMC8215525 DOI: 10.1111/petr.12584] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/16/2015] [Indexed: 01/09/2023]
Abstract
Autoimmune-mediated bowel disease has been reported after pediatric heart transplantation. Recognition and treatment of these patients has been difficult. We describe a patient who responded to steroids and basiliximab therapy after an inflammatory process secondary to abnormal T-cell activation. Our patient is a 28-month-old female who received a heart transplant at five wk of age. At 24 months post-transplant, she developed fever and bloody stools. Initial investigations were significant for an elevated ESR (>120) and CRP (15.2). Symptoms persisted despite bowel rest and mycophenolate discontinuation. Endoscopic evaluation revealed discontinuous ulcerative disease involving esophagus, terminal ileum, right and left colon, necessitating extensive bowel resection. She had additional airway inflammation leading to a TEF at the site of esophageal ulceration, requiring tracheostomy. Immune evaluation revealed autoimmune dysregulation that responded to parenteral methylprednisolone. Chronic basiliximab therapy allowed for successful weaning of steroids with sustained remission. She has been transitioned to sirolimus and tacrolimus maintenance immunosuppression with plans to discontinue basiliximab once off steroids. In conclusion, bowel disease in the setting of pediatric heart transplantation can be severe and refractory to traditional treatment methods. Tailoring immune therapy to activated T cells can result in remission. Basiliximab therapy was used in our patient to maintain steroid-induced remission, but long-term complications of this disease process are unknown.
Collapse
Affiliation(s)
- K. Puri
- The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - S. Kocoshis
- Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - K. Risma
- Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - L. Perez
- Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - C. Hart
- Otolaryngology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - C. Chin
- The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - T. D. Ryan
- The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - J. L. Jefferies
- The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| | - K. R. Schumacher
- Pediatric Cardiology, CS Mott Children’s Hospital, Ann Arbor, MI, USA
| | - C. Castleberry
- The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
| |
Collapse
|
37
|
Hart C, Vogelhuber M, Hafner C, Landthaler M, Berneburg M, Haferkamp S, Herr W, Reichle A. Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial. J Eur Acad Dermatol Venereol 2015; 30:e119-e121. [PMID: 26417987 PMCID: PMC5108438 DOI: 10.1111/jdv.13391] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- C Hart
- Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany
| | - M Vogelhuber
- Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany
| | - C Hafner
- Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany
| | - M Landthaler
- Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany
| | - M Berneburg
- Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany
| | - S Haferkamp
- Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany
| | - W Herr
- Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany
| | - A Reichle
- Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
| |
Collapse
|
38
|
Al-Sukaini A, Hart C, Robinson R, Brown M, Clarke N. Abstract 4350: Prognostic potential of epithelial to mesenchymal transition in prostate cancer at first presentation. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4350] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction and Objective: Metastatic progression of prostate cancer requires a change of state, epithelial to mesenchymal transition (EMT), reducing cell to cell adherence and contact, with associated cell motility and invasion. EMT is one of the hallmarks of cancer and characterisation of the EMT process has defined a panel of EMT biomarkers. Here we investigate the potential of an EMT panel of biomarkers in an unscreened population at first presentation with prostate cancer.
Methods: A prostate Tissue Micro Array (TMA) comprising 2,450 cores containing normal adjacent, prostatic intraepithelial neoplasia and malignant prostate tissue from 524 diagnostic biopsies, linked to an extensive clinical database with long-term outcome, was studied. Expression of a panel of EMT biomarkers, including E-cadherin and vimentin, was assessed using an automated, high throughput fluorescent staining (Leica BOND-MAX), image capture (Carl Zeiss Microimaging Mirax scanner) and quantitative image analysis (Definiens Tissue Studio) protocol. Definiens H-Score was converted to pathological scores prior to univariate and multivariate Cox proportional hazards regression analysis in SPSS.
Results: Expression of an EMT profile predicted a significant reduction in both overall and cancer specific survival. In univariate analysis, low or negative E-cadherin staining was associated with a reduction in median overall survival by 45 months (95% CI: 10.4-79.6; P<0.0001) and a cancer specific mean survival of 80.1 months (95% CI: 45.7-114.5; P<0.0001) when compared to high and intermediate E-cadherin staining. Similarly, high EMT expression, defined as loss of E-cadherin and presence of vimentin, was compared to low EMT expression, defined as preserved E-cadherin and the absence of vimentin. There was a greater reduction in overall median survival in high EMT tumours of 54 months (95% CI: 12.5-95.5; p<0.0001) and cancer specific survival of 93.2 months (95% CI: 62.8-123.7; p<0.0001) when compared to low EMT tumours. Stage, grade, PSA at diagnosis and EMT status was included in the multivariate analysis for cancer specific survival. Both Gleason grade (p = 0.017) and EMT status (p = 0.030) were found to be significant prognostic factors in predicting cancer specific survival.
Conclusions: Loss of E-cadherin and concomitant expression of the EMT marker vimentin are powerful predictors of prostate cancer outcome at first presentation.
Citation Format: Ahmad Al-Sukaini, Claire Hart, Richard Robinson, Mick Brown, Noel Clarke. Prognostic potential of epithelial to mesenchymal transition in prostate cancer at first presentation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4350. doi:10.1158/1538-7445.AM2015-4350
Collapse
Affiliation(s)
- Ahmad Al-Sukaini
- 1Genito Urinary Cancer Research Group, Institute of Cancer Sciences, Manchester, United Kingdom
| | - Claire Hart
- 1Genito Urinary Cancer Research Group, Institute of Cancer Sciences, Manchester, United Kingdom
| | - Richard Robinson
- 1Genito Urinary Cancer Research Group, Institute of Cancer Sciences, Manchester, United Kingdom
| | - Mick Brown
- 1Genito Urinary Cancer Research Group, Institute of Cancer Sciences, Manchester, United Kingdom
| | - Noel Clarke
- 2Dept of Urology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Manchester, United Kingdom
| |
Collapse
|
39
|
Hart C. Erkrankungen von Herz und Gefäßen im Kindesalter. Radiologe 2015; 55:561-9. [DOI: 10.1007/s00117-014-2772-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Kristo I, Wegner P, Voges I, Jerosch-Herold M, Pham M, Gabbert D, Hart C, Kramer H, Rickers C. Diffuse Myocardial Fibrosis and Left Ventricular Diastolic Dysfunction is present in Children and Young Adults with Repaired Aortic Coarctation. Thorac Cardiovasc Surg 2015. [DOI: 10.1055/s-0035-1556041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
41
|
Hart C, Müller M, Scheewe J, Kramer H. Sinusknotendysfunktion (SND) im Langzeitverlauf beim Hypoplastischen Linksherzsyndrom (HLHS). Thorac Cardiovasc Surg 2015. [DOI: 10.1055/s-0035-1555978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Khalifeh H, Johnson S, Howard LM, Borschmann R, Osborn D, Dean K, Hart C, Hogg J, Moran P. Violent and non-violent crime against adults with severe mental illness. Br J Psychiatry 2015; 206:275-82. [PMID: 25698767 DOI: 10.1192/bjp.bp.114.147843] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 09/25/2014] [Indexed: 01/11/2023]
Abstract
BACKGROUND Little is known about the relative extent of crime against people with severe mental illness (SMI). AIMS To assess the prevalence and impact of crime among people with SMI compared with the general population. METHOD A total of 361 psychiatric patients were interviewed using the national crime survey questionnaire, and findings compared with those from 3138 general population controls participating in the contemporaneous national crime survey. RESULTS Past-year crime was experienced by 40% of patients v. 14% of controls (adjusted odds ratio (OR) = 2.8, 95% CI 2.0-3.8); and violent assaults by 19% of patients v. 3% of controls (adjusted OR = 5.3, 95% CI 3.1-8.8). Women with SMI had four-, ten- and four-fold increases in the odds of experiencing domestic, community and sexual violence, respectively. Victims with SMI were more likely to report psychosocial morbidity following violence than victims from the general population. CONCLUSIONS People with SMI are at greatly increased risk of crime and associated morbidity. Violence prevention policies should be particularly focused on people with SMI.
Collapse
Affiliation(s)
- H Khalifeh
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - S Johnson
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - L M Howard
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - R Borschmann
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - D Osborn
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - K Dean
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - C Hart
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - J Hogg
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| | - P Moran
- H. Khalifeh, MSc, MRCPsych, S. Johnson, MD, MRCPsych, Division of Psychiatry, University College London, London; L. M. Howard, PhD, MRCPsych, R. Borschmann, DClinPsy, David Goldberg Centre, Institute of Psychiatry, London; D. Osborn, PhD, MRCPsych, Division of Psychiatry, University College London, London; K. Dean, PhD, MRCPsych, Institute of Psychiatry, London, and School of Psychiatry, University of New South Wales and Justice Health & Forensic Mental Health Network; C. Hart, MSc, J. Hogg, MSc, P. Moran, PhD, MRCPsych, David Goldberg Centre, Institute of Psychiatry, London, UK
| |
Collapse
|
43
|
Kang B, Yeligar S, Bijli K, Adesina S, Kleinhenz J, Murphy T, Sutliff R, Hart C. Loss of PPARγ Promotes Mitochondrial Dysfunction through Downregulation of PGC1α. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.1031.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Bum‐Yong Kang
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| | - Samantha Yeligar
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| | - Kaiser Bijli
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| | - Sherry Adesina
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| | - Jennifer Kleinhenz
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| | - Tamara Murphy
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| | - Roy Sutliff
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| | - C Hart
- Department of MedicineAtlanta Veterans Affairs and Emory University Medical CentersDecaturGAUnited States
| |
Collapse
|
44
|
Abstract
INTRODUCTION The laparoscopic approach to repairing ventral and incisional hernias has gained increasing popularity worldwide. We reviewed the experience of laparoscopic ventral hernia repair at a district general hospital in the UK with particular reference to patients with massive defects (diameter ≥15cm) and the morbidly obese. METHODS A total of 144 patients underwent laparoscopic ventral (incisional or umbilical/paraumbilical) hernia repair between April 2007 and September 2012. RESULTS The prevalence of conversion to open surgery was 2.8%. The prevalence of postoperative complications was 3.5%. Median postoperative follow-up was 30.2 months. A total of 5.6% cases suffered late complications and 2.8% developed recurrence. Thirty-four patients underwent repair of defects ≥10cm in diameter with a prevalence of recurrence of 5.6%. Sixteen patients underwent repair of 'massive' incisional hernia (diameter ≥15cm) with a prevalence of recurrence of 12.5%. Sixteen patients with a body mass index (BMI) ≥40kg/m(2) (range, 40-61kg/m(2)) underwent laparoscopic repair with a prevalence of recurrence of 6.3% (p>0.05 vs BMI <40kg/m(2)). CONCLUSIONS Laparoscopic ventral hernia repair can be carried out safely with a low prevalence of recurrence. It may have advantages in morbidly obese patients in whom open repair would represent a significant undertaking. Laparoscopic ventral hernia repair may be used in cases of large and massive hernias, in which the risk of recurrence increases but is comparable with open repair and associated with low morbidity.
Collapse
Affiliation(s)
- C D Mann
- Northampton General Hospital, UK
| | | | | | | |
Collapse
|
45
|
Khalifeh H, Moran P, Borschmann R, Dean K, Hart C, Hogg J, Osborn D, Johnson S, Howard LM. Domestic and sexual violence against patients with severe mental illness. Psychol Med 2015; 45:875-886. [PMID: 25180908 PMCID: PMC4413870 DOI: 10.1017/s0033291714001962] [Citation(s) in RCA: 105] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Revised: 07/08/2014] [Accepted: 07/18/2014] [Indexed: 11/05/2022]
Abstract
BACKGROUND Domestic and sexual violence are significant public health problems but little is known about the extent to which men and women with severe mental illness (SMI) are at risk compared with the general population. We aimed to compare the prevalence and impact of violence against SMI patients and the general population. METHOD Three hundred and three randomly recruited psychiatric patients, in contact with community services for ⩾ 1 year, were interviewed using the British Crime Survey domestic/sexual violence questionnaire. Prevalence and correlates of violence in this sample were compared with those from 22 606 general population controls participating in the contemporaneous 2011/12 national crime survey. RESULTS Past-year domestic violence was reported by 27% v. 9% of SMI and control women, respectively [odds ratio (OR) adjusted for socio-demographics, aOR 2.7, 95% confidence interval (CI) 1.7-4.0], and by 13% v. 5% of SMI and control men, respectively (aOR 1.6, 95% CI 1.0-2.8). Past-year sexual violence was reported by 10% v. 2.0% of SMI and control women respectively (aOR 2.9, 95% CI 1.4-5.8). Family (non-partner) violence comprised a greater proportion of overall domestic violence among SMI than control victims (63% v. 35%, p < 0.01). Adulthood serious sexual assault led to attempted suicide more often among SMI than control female victims (53% v. 3.4%, p < 0.001). CONCLUSIONS Compared to the general population, patients with SMI are at substantially increased risk of domestic and sexual violence, with a relative excess of family violence and adverse health impact following victimization. Psychiatric services, and public health and criminal justice policies, need to address domestic and sexual violence in this at-risk group.
Collapse
Affiliation(s)
- H. Khalifeh
- Division of Psychiatry, Faculty of Brain
Sciences, UCL (University College London),
UK
| | - P. Moran
- Health Service and Population Research Department,
Institute of Psychiatry, King's College London,
UK
| | - R. Borschmann
- Health Service and Population Research Department,
Institute of Psychiatry, King's College London,
UK
| | - K. Dean
- School of Psychiatry, UNSW
and Justice Health and Forensic Mental Health Network,
NSW, Australia
| | - C. Hart
- Health Service and Population Research Department,
Institute of Psychiatry, King's College London,
UK
| | - J. Hogg
- Health Service and Population Research Department,
Institute of Psychiatry, King's College London,
UK
| | - D. Osborn
- Division of Psychiatry, Faculty of Brain
Sciences, UCL (University College London),
UK
| | - S. Johnson
- Division of Psychiatry, Faculty of Brain
Sciences, UCL (University College London),
UK
| | - L. M. Howard
- Health Service and Population Research Department,
Institute of Psychiatry, King's College London,
UK
| |
Collapse
|
46
|
Hart C, Spannagl M. [Coagulation disorders in the intensive care station]. Internist (Berl) 2014; 55:521-8. [PMID: 24715275 DOI: 10.1007/s00108-013-3422-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Coagulation disorders are frequently encountered in the intensive care unit (ICU) and are challenging due to a variety of potential etiologies. Critically ill patients with coagulation abnormalities may present with an increased risk of bleeding, show coagulation activation resulting in thromboembolism, or have no specific symptoms. Hemostatic abnormalities observed in ICU patients range from isolated thrombocytopenia or prolonged global clotting tests to complex and life-threatening coagulation defects. Successful management of coagulation disorders requires prompt and accurate identification of the underlying cause. This review describes the most frequently occurring diagnoses found in intensive care patients with thrombocytopenia and coagulation test abnormalities and summarizes appropriate diagnostic interventions and current approaches to differential diagnosis.
Collapse
Affiliation(s)
- C Hart
- Klinik und Poliklinik für Innere Medizin III, Universitätsklinikum Regensburg, Franz-Josef-Strauss Allee 11, Regensburg, 93053, Deutschland,
| | | |
Collapse
|
47
|
Banka S, de Goede C, Yue WW, Morris AAM, von Bremen B, Chandler KE, Feichtinger RG, Hart C, Khan N, Lunzer V, Mataković L, Marquardt T, Makowski C, Prokisch H, Debus O, Nosaka K, Sonwalkar H, Zimmermann FA, Sperl W, Mayr JA. Expanding the clinical and molecular spectrum of thiamine pyrophosphokinase deficiency: a treatable neurological disorder caused by TPK1 mutations. Mol Genet Metab 2014; 113:301-6. [PMID: 25458521 DOI: 10.1016/j.ymgme.2014.09.010] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2014] [Revised: 09/15/2014] [Accepted: 09/15/2014] [Indexed: 10/24/2022]
Abstract
Thiamine pyrophosphokinase (TPK) produces thiamine pyrophosphate, a cofactor for a number of enzymes, including pyruvate dehydrogenase and 2-ketoglutarate dehydrogenase. Episodic encephalopathy type thiamine metabolism dysfunction (OMIM 614458) due to TPK1 mutations is a recently described rare disorder. The mechanism of the disease, its phenotype and treatment are not entirely clear. We present two patients with novel homozygous TPK1 mutations (Patient 1 with p.Ser160Leu and Patient 2 with p.Asp222His). Unlike the previously described phenotype, Patient 2 presented with a Leigh syndrome like non-episodic early-onset global developmental delay, thus extending the phenotypic spectrum of the disorder. We, therefore, propose that TPK deficiency may be a better name for the condition. The two cases help to further refine the neuroradiological features of TPK deficiency and show that MRI changes can be either fleeting or progressive and can affect either white or gray matter. We also show that in some cases lactic acidosis can be absent and 2-ketoglutaric aciduria may be the only biochemical marker. Furthermore, we have established the assays for TPK enzyme activity measurement and thiamine pyrophosphate quantification in frozen muscle and blood. These tests will help to diagnose or confirm the diagnosis of TPK deficiency in a clinical setting. Early thiamine supplementation prevented encephalopathic episodes and improved developmental progression of Patient 1, emphasizing the importance of early diagnosis and treatment of TPK deficiency. We present evidence suggesting that thiamine supplementation may rescue TPK enzyme activity. Lastly, in silico protein structural analysis shows that the p.Ser160Leu mutation is predicted to interfere with TPK dimerization, which may be a novel mechanism for the disease.
Collapse
Affiliation(s)
- Siddharth Banka
- Faculty of Medical and Human Sciences, Manchester Centre for Genomic Medicine, Institute of Human Development, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK; Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Manchester, UK.
| | | | - Wyatt W Yue
- Structural Genomics Consortium, Old Road Campus Research Building, University of Oxford, Oxford, UK
| | - Andrew A M Morris
- Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Manchester, UK
| | - Beate von Bremen
- Department of Paediatrics, Royal Blackburn Hospital, Blackburn, UK
| | - Kate E Chandler
- Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Manchester, UK
| | - René G Feichtinger
- Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria
| | - Claire Hart
- Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Manchester, UK
| | - Nasaim Khan
- Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Manchester, UK
| | - Verena Lunzer
- Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria
| | - Lavinija Mataković
- Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria
| | - Thorsten Marquardt
- Department of General Paediatrics, University Children's Hospital Münster, Germany
| | - Christine Makowski
- Department of Paediatrics, Technische Universität München, Munich, Germany
| | - Holger Prokisch
- Institute of Human Genetics, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - Otfried Debus
- Clemenshospital, Children's Hospital, Münster, Germany
| | - Kazuto Nosaka
- Department of Chemistry, Hyogo College of Medicine, Nishinomiya, Japan
| | | | - Franz A Zimmermann
- Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria
| | - Wolfgang Sperl
- Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria
| | - Johannes A Mayr
- Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria
| |
Collapse
|
48
|
Affiliation(s)
| | - W. Richard Walker
- Department of Psychological Sciences; Winston-Salem State University; Winston-Salem USA
| | - Shawnda Marsh
- Department of Psychological Sciences; Winston-Salem State University; Winston-Salem USA
| | - Claire Hart
- School of Psychology; University of Southampton; Southampton UK
| | | |
Collapse
|
49
|
Khalifeh H, Moran P, Borschmann R, Dean K, Hart C, Hogg J, Osborn D, Johnson S, Howard L. Domestic and sexual violence against people with severe mental illness: comparisons with the 2011/2012 National Crime survey for England and Wales. Eur J Public Health 2014. [DOI: 10.1093/eurpub/cku162.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Hart C, Gruer L. Comparing the impact of personal and parental risk factors, and parental lifespan on all-cause mortality and cardiovascular disease: findings from the 1996 Midspan Family Study in Scotland. Eur J Public Health 2014. [DOI: 10.1093/eurpub/cku166.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|